BELLUS Health Inc (TSE:BLU)’s stock price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $6.20 and traded as high as $9.57. BELLUS Health shares last traded at $9.57, with a volume of 15,959 shares trading hands.

Separately, Bloom Burton reiterated a “buy” rating on shares of BELLUS Health in a research report on Thursday, August 1st.

The company has a current ratio of 6.11, a quick ratio of 6.04 and a debt-to-equity ratio of 0.56. The firm has a market cap of $422.05 million and a price-to-earnings ratio of -20.64. The stock has a 50-day moving average of C$6.33 and a two-hundred day moving average of C$2.94.

In related news, Director Franklin Milan Berger purchased 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 20th. The stock was acquired at an average price of C$2.70 per share, for a total transaction of C$134,925.00. Following the transaction, the director now directly owns 1,502,108 shares of the company’s stock, valued at approximately C$4,053,438.44.

About BELLUS Health (TSE:BLU)

BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease.

Featured Story: Stock Portfolio Tracker

Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.